Redcare Pharmacy stock gains as Q3 profit and Rx sales advance

Redcare Pharmacy delivered a stronger third quarter on October 29, with German prescription sales driving growth and profitability. The latest Lang & Schwarz quote was 75.40 euros at 18:31 CET on Monday, November 2, 0.66 percent below the Xetra close of 75.90 euros from the same day. Compared with the 69.90-euro quote cited in the company stock report of November 1, the share price was 7.87 percent higher.

The company said in its Q3 results release that group revenue increased 18 percent year over year to 847 million euros. Prescription revenue rose 31 percent to 358 million euros, with Germany up 56 percent to 197 million euros. Non-prescription revenue grew 9 percent to 489 million euros.

Profitability Moves Higher

Adjusted EBITDA rose 68 percent year over year to 29 million euros, lifting the margin to 3.4 percent from 2.4 percent. Net income reached 1 million euros, marking a second consecutive profitable quarter, while quarterly free cash flow amounted to 15 million euros.

The active customer base reached 15.2 million at the end of September, up 1.5 million from a year earlier. DACH adjusted EBITDA rose to 29 million euros and its margin reached 4.2 percent, while the international segment remained at a negative adjusted EBITDA of 1 million euros.

Guidance Remains Unchanged

Redcare Pharmacy confirmed its upgraded 2026 targets: total revenue growth of 16 to 18 percent, non-prescription growth of 10 to 12 percent, German prescription revenue of 730 million to 760 million euros and an adjusted EBITDA margin of 2.5 to 3.0 percent. The prescription business remains the central earnings driver, while the slower start to non-prescription sales keeps execution in focus.

The next scheduled company publication is the FY 2026 trading update on January 11, 2027. Investors can follow the real-time quote of Redcare Pharmacy stock for further trading developments.

European equities provide the broader backdrop through Euro Stoxx 50 market reports.

More news and analyses are available on Redcare Pharmacy stock.